Business Details
16 Years
experience
Biopharmaceutical Innovation for Neurodegenerative Disease Treatment
Since 2010, Neuropathix has been a leader in the research, development, and commercialization of patented novel therapeutics targeting inflammation, neurodegeneration, and oxidative stress. Our focus on synthetic cannabidiol (CBD)-inspired molecules has led to the creation of a proprietary platform of innovative compounds, including our lead candidate KLS-13019, which demonstrates significantly improved potency, bioavailability, and safety compared to CBD. As the exclusive licensee of the U.S. Government Patent 6,630,507 for cannabinoids as antioxidants and neuroprotectants, we have advanced pre-clinical and clinical research programs for conditions such as chemotherapy-induced peripheral neuropathy (CIPN), hepatic encephalopathy (HE), and traumatic brain injury (TBI). Our subsidiary, Kannalife Sciences, has secured over $3.2 million in grants from the National Institutes of Health (NIH) to support this groundbreaking work.With a scientific team boasting over 75 years of combined pharmaceutical experience and 65 patents, we collaborate with globally recognized leaders in API manufacturing and drug formulation. Our intellectual property portfolio includes multiple U.S. and international patents, reflecting our commitment to innovation. Headquartered at the Pennsylvania Biotechnology Center in Doylestown, PA, we are dedicated to addressing significant unmet medical needs while adhering to the highest standards of scientific rigor and ethical responsibility.
Services
Cannabinoid Therapeutics Development
Neurodegenerative Disease Research
Pre-Clinical Drug Discovery
Oxidative Stress Treatment
Inflammation Targeting Therapeutics
Details
- Year established: 2010
Highlights and features
- We have led cannabinoid research since 2010 with a patented platform of synthetic CBD-inspired molecules.
- Our lead compound KLS-13019 demonstrates 200x greater potency and 10x better bioavailability than CBD.
- We hold exclusive rights to NIH patents underpinning antioxidant and neuroprotectant cannabinoid therapies.
- Our scientific team has 75+ years of combined pharmaceutical experience and 65 issued patents.
- We have secured $3.27 million in NIH grants to advance our neurodegenerative disease research programs.
Services
Cannabinoid Therapeutics Development
We engineer synthetic CBD-inspired molecules with enhanced pharmacological properties to treat neurodegenerative conditions. Our proprietary platform improves potency, bioavailability, and safety profiles compared to natural CBD. This work builds on exclusive NIH patents and decades of pre-clinical research.
Neurodegenerative Disease Research
Our programs target diseases like CIPN, HE, and TBI through novel cannabinoid-based therapies. We focus on reversing oxidative stress and inflammation mechanisms in these conditions. Our research includes IND-enabling studies and peer-reviewed publications validating therapeutic efficacy.
Pre-Clinical Drug Discovery
We conduct comprehensive pre-clinical evaluations of cannabinoid-inspired compounds in cellular and animal models. This includes pharmacokinetic/pharmacodynamic profiling and safety assessments. Our work has produced eight peer-reviewed studies on KLS-13019's mechanisms and effects.
Oxidative Stress Treatment
Our patented compounds target oxidative stress pathways implicated in neurodegenerative diseases. By optimizing neuroprotective potency against oxidative toxicity, we address conditions like hepatic encephalopathy and chemotherapy-induced neuropathy. This research has resulted in multiple international patents.
Inflammation Targeting Therapeutics
We develop therapeutics that modulate inflammatory responses in neurological and hepatic conditions. Our GPR55 antagonist KLS-13019 demonstrates potent anti-inflammatory effects in pre-clinical models. This work supports potential applications for chronic pain and neuroinflammatory disorders.
People
Dean Petkanas
Chairman & CEO
Dean Petkanas brings decades of pharmaceutical leadership to Neuropathix, guiding strategic direction and business development. His expertise spans drug commercialization and corporate governance, driving the company's mission to address unmet medical needs through innovative cannabinoid research.
William A. Kinney
Chief Scientific Officer
Dr. William Kinney oversees scientific operations with extensive experience in drug discovery and development. His leadership in cannabinoid research has advanced Neuropathix's pipeline, including the patented KLS-13019 compound. He has contributed to numerous peer-reviewed publications validating the company's therapeutic approach.
Mark McDonnell
Chief Chemist
Dr. Mark McDonnell leads chemical synthesis and formulation efforts, instrumental in developing Neuropathix's proprietary cannabinoid-inspired molecules. His work on KLS-13019's chemical optimization has achieved significant improvements in potency and bioavailability compared to natural CBD.
Douglas Brenneman
Chief Pharmacologist
Dr. Douglas Brenneman directs pharmacological research, focusing on mechanisms of neuroprotection and anti-inflammatory effects. His studies have demonstrated KLS-13019's efficacy in pre-clinical models of neuropathic pain and oxidative stress-related diseases.
Tage Honor
Chairman of Scientific Advisory Board
Dr. Tage Honor provides strategic scientific guidance as chairman of the advisory board. With a distinguished career in neuroscience research, he supports Neuropathix's mission to translate cannabinoid science into novel therapeutics for neurodegenerative conditions.
Questions
What diseases does Neuropathix target with its therapeutics?
We focus on neurodegenerative and inflammatory conditions including chemotherapy-induced peripheral neuropathy (CIPN), hepatic encephalopathy (HE), traumatic brain injury (TBI), and oxidative stress-related diseases.
What makes KLS-13019 different from CBD?
KLS-13019 is a synthetic cannabinoid-inspired molecule with 200x greater potency, 10x better bioavailability, and 5x improved safety profile compared to natural CBD, based on pre-clinical studies.
How is Neuropathix funded?
Our research is supported by NIH grants totaling $3.27 million, including a $2.97 million Phase 2 study grant from NINDS for neuropathic pain research.
Where is Neuropathix's research conducted?
Our pre-clinical and clinical research takes place at the Pennsylvania Biotechnology Center in Doylestown, PA, our primary research facility since 2010.
What intellectual property does Neuropathix hold?
We hold U.S. Patents 9,611,213 and 10,004,722 for KLS-13019 and related compounds, with additional patents granted in Japan, Russia, China, Europe, and pending in Brazil and India.
What scientific recognition has Neuropathix received?
Our work has been published in eight peer-reviewed journals, including the British Journal of Pharmacology and the Journal of Pharmacology and Experimental Therapeutics, validating our therapeutic approach.